Sambucol
An elderberry extract brand developed in Israel in 1991 by a virologist, now marketed globally on decades-old clinical research into black elderberry.
Founded
1991 (developed), with U.S. marketing history dating to the 1990s–2000s
Headquarters
Originally Jerusalem, Israel (developed by Razei Bar); international rights have changed hands since a 2006 acquisition by Healthcare Brands International
Ownership
Not confirmed
Verification
No USP or NSF verification found; relies on citations to published clinical trials on its specific elderberry extract rather than a manufacturing-audit seal
History
Sambucol was developed in 1991 by Dr. Madeleine Mumcuoglu, an Israeli virologist who researched the antiviral properties of black elderberry (Sambucus nigra) extract over more than a decade at Hadassah Medical Center in Jerusalem. It was originally produced by the Jerusalem-based company Razei Bar.
The product built its reputation on small, industry-funded clinical trials, including a placebo-controlled study on flu symptom duration and later in-vitro testing suggesting activity against avian influenza strains. In 2006, Sambucol was acquired by Healthcare Brands International with the stated goal of expanding it into a larger global consumer brand; distribution rights have shifted among companies in different markets since.
In the U.S., a related company (Nature's Way, which distributed Sambucol) was investigated by the FTC in the early 2000s over advertising claiming Sambucol was effective in treating and preventing influenza and West Nile virus. The FTC closed its investigation after the company halted the campaign, including canceling a planned press conference, and staff found the company had adequate substantiation for the narrower claims it continued to make, but the episode illustrates the regulatory line around disease-treatment claims for an unapproved supplement.
Why it is trusted
- +Has more published, industry-funded human clinical research behind its specific extract than most single-ingredient supplement brands, which is unusual for the category.
- +Long, consistent formulation history (a standardized black elderberry extract) rather than frequent reformulation.
- +Was the subject of a 2002 FTC advertising investigation over unsubstantiated flu- and West-Nile-virus treatment claims tied to a marketing campaign; the campaign was halted before the FTC took formal action, which is a mitigating fact but does not erase that the claims were made in the first place.
- +No independent purity or potency certification (USP, NSF) was found for current Sambucol products during the September 2026 review. Certification can vary by product and market.
Where we would be careful
- −In 2002 the FTC investigated advertising claims that Sambucol treats or prevents influenza and West Nile virus; the campaign was cancelled and the investigation closed, but it is a documented instance of a disease-treatment claim crossing regulatory lines.
- −Elderberry supplements broadly have drawn FDA and FTC attention industry-wide for immune and antiviral claims that outrun the underlying evidence, read the specific claim on the package, not the brand's history.
- −Current ownership and manufacturing arrangements were not confirmed during the September 2026 review.
Where Sambucol ranks
Sources
- FTC staff closing letter, Nature's Way Products, Inc. (Sambucol advertising investigation), June 2002: https://www.ftc.gov/sites/default/files/documents/closing_letters/natures-way-products-inc./natureswayclose.pdf
- NutraIngredients, "New company aims to make Sambucol a global consumer brand," October 2006: https://www.nutraingredients.com/Article/2006/10/26/New-company-aims-to-make-Sambucol-a-global-consumer-brand/
- ISRAEL21c, "Israel's elderberry remedy Sambucol provides solution to U.S. flu vaccine shortage," October 2004: https://archive.israel21c.org/israels-elderberry-remedy-sambucol-provides-solution-to-u-s-flu-vaccine-shortage/